Your data on MRCVSonline
The nature of the services provided by Vision Media means that we might obtain certain information about you.
Please read our Data Protection and Privacy Policy for details.

In addition, (with your consent) some parts of our website may store a 'cookie' in your browser for the purposes of
functionality or performance monitoring.
Click here to manage your settings.
If you would like to forward this story on to a friend, simply fill in the form below and click send.

Your friend's email:
Your email:
Your name:
 
 
Send Cancel

Pergolide helps manage equine PPID, study finds
The pergolide treatment did not have any effect on horses which were diagnosed with ID only.
The drug reduced blood insulin levels in horses with both PPID and ID.

A new study has highlighted the benefits of using pergolide mesylate to treat horses diagnosed with pituitary pars intermedia dysfunction (PPID).

The drug, which is already commonly used for treating the condition, proved to be effective in reducing the amount of insulin produced by horses when eating.

PPID, also known as Cushing's syndrome, affects the pituitary gland at the base of a horse's brain which produces hormones in response to brain signals. When damaged due to PPID, there can be excessive production of normal hormones, leading to issues such as laminitis and weight loss.

The risk of developing laminitis is higher in horses also diagnosed with insulin dysregulation (ID). A high concentration of insulin is now recognised as the leading cause of laminitis in the UK.

A research project, published by the University of Melbourne, sought to investigate how effective pergolide was at managing the clinical signs of PPID.

The study saw 16 senior horses (eight with PPID and ID, eight with ID only) take part in a standard meal test. Researchers measured the horses' insulin concentration before and after they had eaten a high starch meal.

All of the horses did the standard meal test twice, once after four weeks of pergolide treatment and once without pergolide treatment.

The results revealed that pergolide was an effective treatment for horses with both PPID and ID. Horses treated with pergolide recorded blood insulin levels at the same level as horses that only had ID.

However, the pergolide treatment did not have any effect on horses which were diagnosed with ID only. Researchers say that this highlights the importance of testing for PPID and ID separately, as treating one may not manage the other.

The study also found that, even when treated with pergolide, the horses diagnosed with PPID or ID still produced more insulin from starchy, sugary meals than healthy horses. Researchers say that a low sugar and starch diet remains vital for managing horses with PPID and ID.

The full study has been published in the Equine Veterinary Journal.

Image © Shutterstock

Become a member or log in to add this story to your CPD history

Vets launch new podcast for pet owners

News Story 1
 Two independent vets have launched a podcast to help owners strengthen their bond with pets. Dr Maggie Roberts and Dr Vanessa Howie, who have worked in both veterinary practice and major charities, are keen to use their experience to enable people to give pets a better life.

The venture, called Vets Talking Pets, provides advice and information on a range of topics, including how to select a suitable pet, where to obtain them and how to get the best out of your vet. Maggie and Vanessa will also discuss sensitive subjects, including end-of-life care, raw food diets and the cost of veterinary care.

The podcast can be found on all the usual podcast sites, including Podbean, Apple, Amazon Music and YouTube. 

Click here for more...
News Shorts
VMD issues guidance on AVM-GSL packaging

The Veterinary Medicines Directorate (VMD) has shared advice on its requirements for medicines considered AVM-GSL.

The guidance explains the information that should be on the outer package, and sets out the typical maximum pack size for an AVM-GSL product. It also describes the user-friendly language, structure and phrases required on packaging and product leaflets.

AVM-GSL products do not require discussion between the purchaser and a veterinary professional. This means that clear product information is needed to support sales choices.

The information will be useful for submitting new products to the AVM-GSL category and lowering the distribution category of products from NFA-VPS to AVM-GSL.

The VMD's guidance can be accessed here.